Oct 24 (Reuters) - Tyra Biosciences Inc :
* TYRA BIOSCIENCES REPORTS INTERIM CLINICAL PROOF-OF-CONCEPT DATA FOR TYRA-300, AN INVESTIGATIONAL ORAL FGFR3-SELECTIVE INHIBITOR, IN PHASE 1/2 SURF301 STUDY IN PATIENTS WITH METASTATIC UROTHELIAL CANCER $(MUC)$
* TYRA BIOSCIENCES INC - TYRA-300 GENERALLY WELL-TOLERATED WITH INFREQUENT FGFR2/FGFR1 TOXICITIES
* TYRA BIOSCIENCES INC - 4 SERIOUS ADVERSE EVENTS RELATED TO TYRA-300
* TYRA BIOSCIENCES INC - POSITIVE SAFETY RESULTS ACROSS ALL QD DOSES
Source text for Eikon: Further company coverage:
((Reuters.Brief@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.